Venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary thromboembolism (PTE), is the third most common vascular disease worldwide. Anticoagulant therapy is the fundamental treatment for venous thromboembolism. Compared to heparin, oral anticoagulants usually have a lower risk of bleeding and do not require monitoring of coagulation function, making them more convenient to use. However, currently available products are in tablet form, and there is a clinical urgency for innovative dosage forms that are more convenient for patients with difficulty swallowing such as stroke patients and elderly people.

ASN006 is a new dosage form for the treatment and prevention of venous thromboembolism, designed to facilitate administration for patients with difficulty swallowing. Currently, its NDA application is under FDA review.